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SUMMARY 
Background: Irritable bowel syndrome (IBS) is a complex, heterogeneous disease which can 
be challenging to diagnose. No study has identified and assessed the accuracy of all 
available methods of diagnosing IBS.  
Aims: We conducted a systematic review of the literature to identify and assess accuracy of 
symptom-based diagnostic criteria, biomarkers, psychological markers, or combinations 
thereof. 
Methods: MEDLINE, EMBASE and EMBASE Classic were searched (until April 2015) to 
identify studies reporting accuracy of available methods to diagnose IBS in adult 
populations. Eligible studies assessed accuracy of these diagnostic tests against an accepted 
reference standard. Data were extracted to calculate positive and negative likelihood ratios, 
with 95% confidence intervals (CIs), of the diagnostic test utilised. Where more than one 
study used the same test, data were pooled in a meta-analysis.  
Results: 22 studies (7106 patients) were eligible. Positive and negative likelihood ratios of 
the current gold standard, the Rome III criteria, were 3.35 (95% CI 2.97-3.79) and 0.39 (95% 
CI 0.34-0.46), similar to other symptom-based criteria. Eleven biomarkers performed no 
better than symptom-based criteria. Psychological markers performed well in one study. 
Five different combinations were assessed. The best in terms of positive likelihood ratio was 
faecal calprotectin, intestinal permeability, and Rome I criteria (26.4; 95% CI 11.4-61.9), and 
in terms of negative likelihood ratio serum-based biomarkers and psychological markers 
(0.18; 95% CI 0.12-0.25). 
Conclusions: Symptom-based diagnostic criteria, biomarkers, and psychological markers 
performed modestly in predicting IBS. Combining symptoms with markers appears more 
effective, and may represent the way forward in diagnosing IBS. 
INTRODUCTION 
 
 Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder 
characterised by abdominal pain associated with a change in stool form and/or 
frequency.(1) The condition has an estimated prevalence of up to 20% in Western 
populations,(2) and the impact of IBS socially and economically is significant, with up to 12% 
of IBS patients having to stop work completely. There is an estimated direct cost per patient 
to the US economy of between $742 and $7547.(3) The pathogenesis of IBS is poorly 
understood and, as yet, no unifying structural or physiological cause has been identified. 
Furthermore, making a positive diagnosis of IBS is challenging as the symptoms often 
overlap with those of organic GI disease such as colorectal cancer,(4)  inflammatory bowel 
disease,(5) bile acid malabsorption,(6) and coeliac disease.(7, 8)  
 Symptom-based diagnostic criteria were developed to aid in making a positive 
diagnosis of IBS and are the current gold standard, the latest iteration of these being the 
Rome III criteria.(1) However, these criteria have been criticised for being overly complex 
and impractical in a clinical setting, particularly in primary care where the majority of IBS is 
diagnosed and managed.(9, 10) Partly as a consequence of this, interest has grown in 
developing novel biomarkers, measurable biological characteristics including physiological 
responses, proteins, genes and metabolites, as a diagnostic tool.(11) Patients with IBS are 
more likely to have higher levels of anxiety, neuroticism, or mood instability when 
compared to healthy individuals and those with other lower GI disorders.(12-15) As a result, 
studies have also been conducted to assess whether measures of psychological wellbeing 
can aid in the diagnosis of IBS.  
 We, and others, have previously examined the accuracy of symptom-based 
diagnostic criteria in predicting IBS. (16, 17)  However, since this meta-analysis was 
performed there have been more studies published, as well as the description of novel 
attempts to diagnose IBS. As the Rome IV process for functional GI disorders is due to report 
in 2016, a summary of the accuracy of all available approaches, including symptoms, 
biomarkers, psychological markers, and combinations of the above would seem timely.  We 
have therefore conducted an updated systematic review and meta-analysis examining this 
issue.  
 
 
 
 
 
  
METHODS 
 
Search Strategy and Study Selection 
The systematic review was performed according to the Cochrane Methods Group on 
screening and diagnostic tests guidelines.(18)   A search of the medical literature was 
conducted using MEDLINE (January 1946 to April 2015), EMBASE, and EMBASE classic (1947 
to April 2015). Eligible studies were required to report prospectively on  adult (A?16 years of 
age) patients with lower GI symptoms, and had to assess the accuracy of one or more of the 
available accepted symptom-based diagnostic criteria for IBS, biomarkers, psychological 
markers, or combinations thereof, in diagnosing IBS against an accepted reference standard, 
ƚĂŬĞŶĂƐďĞŝŶŐĂƉŚǇƐŝĐŝĂŶ ?ƐĚŝĂŐŶŽƐŝƐŽĨ/^ ?ĂŶŽƚŚĞƌƐĞƚŽĨĂĐĐĞƉƚĞĚĚŝĂŐŶŽƐƚŝĐĐƌŝƚĞƌŝĂ ?Žƌ
the absence of an organic explanation for these symptoms, such as IBD, microscopic colitis, 
or colorectal cancer, following lower GI endoscopy (Table 1). When assessing the accuracy 
of symptom-based diagnostic criteria, the reference standard was mandated as negative 
lower GI investigations, but when assessing the accuracy of novel biomarkers this could 
either be accepted symptom-based diagnostic ĐƌŝƚĞƌŝĂŽƌĂƉŚǇƐŝĐŝĂŶ ?ƐĚŝĂŐŶŽƐŝƐŽĨ/^ ? We 
did not consider studies that applied an accepted test for organic disease, such as faecal 
calprotectin or lactoferrin, and therefore effectively reached a diagnosis of IBS by exclusion 
of the specific organic disease that the test was designed to detect, eligible for inclusion in 
this meta-analysis.  
Search terms used to identify potentially relevant publications were: irritable bowel 
syndrome, IBS, functional diseases, colon or functional adj5 bowel. These were combined, 
using the set operator AND, with the following search terms: Kruis, Manning, Rome 1, Rome 
I, Rome 2, Rome II, Rome3, Rome III, biomarker, f$ecal biomarker, psychological marker, 
metabolite, transit time, colonic motility, small intestinal motility, visceral hypersensitivity, 
pain, bile acid, cytokine, mast cell, intestinal permeability, chromogranin or secretogranin. 
These were again combined using the set operator AND with the search terms sensitivity or 
specificity. There were no language restrictions and abstracts of the papers identified by the 
initial search were evaluated by the lead author for appropriateness to the study question. 
All potentially relevant papers were obtained and evaluated in detail. Foreign language 
papers were translated. Abstract books of conference proceedings between 2007 and 2014 
were hand-searched to identify potentially eligible studies published only in abstract form. 
The bibliographies of all identified relevant studies were used to perform a recursive search 
of the literature. Articles were assessed independently by two reviewers using pre-designed 
eligibility forms, according to the prospectively defined eligibility criteria. Any disagreement 
between investigators was resolved by consensus.  
 
Data Extraction 
 All data were extracted independently by two reviewers on to a Microsoft Excel 
spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA) as total number 
of patients with IBS, total number of IBS patients testing positive for IBS using the diagnostic 
criteria, biomarker, psychological marker, or combination thereof under study, total number 
of non-IBS patients, and the total number of non-IBS patients testing positive for IBS using 
the same diagnostic test. In addition, the following clinical data were extracted for each 
study: setting (primary or secondary care), number of centres, country of origin, and 
diagnostic test applied. 
 
 
Data Synthesis and Statistical Analysis 
The degree of agreement between investigators, in judging study eligibility, was 
measured using the Kappa statistic. The accuracy of diagnostic tests is often summarised 
ƵƐŝŶŐƐĞŶƐŝƚŝǀŝƚǇĂŶĚƐƉĞĐŝĨŝĐŝƚǇ ?ůƚŚŽƵŐŚƚŚĞƐĞĂƌĞƵƐĞĨƵůŵĞĂƐƵƌĞƐŽĨĂƚĞƐƚ ?ƐƉĞƌĨŽƌŵĂŶĐĞ ?
they provide the probability of the test being positive if the disease of interest is present, or 
the probability of the test being negative if the disease is absent. However, for a physician 
consulting with a patient it is more useful to know the probability of the patient truly having 
the disease if the test is positive, or truly not having the disease if the test is negative. These 
are known as the positive and negative predictive values of the test.  
One of the limitations of positive and negative predictive values is that their 
magnitude varies according to the prevalence of the disease under study. For this reason, 
more useful summary measures of the diagnostic accuracy of a test are the positive and 
negative likelihood ratios (LR). These are derived from the sensitivity and specificity of a 
test, which are fixed, and therefore the advantage of using LRs over predictive values is that 
LRs do not vary to the same degree as predictive values with changes in the prevalence of 
the disease. (19)The positive LR is derived from the formula:  
௦௘௡௦௜௧௜௩௜௧௬ଵି௦௣௘௖௜௙௜௖௜௧௬ while the negative 
LR is derived from the formula:  
ଵି௦௘௡௦௜௧௜௩௜௧௬௦௣௘௖௜௙௜௖௜௧௬ . The positive LR describes the likelihood of an 
individual having the disease if the diagnostic test is positive, and the negative LR the 
likelihood of an individual not having the disease if the test is negative. As a rule of thumb, 
positive LRs above 10 are very useful in ruling in a disease, and negative LRs below 0.1 are 
very useful in ruling out a disease. However, in rare diseases, which have a low prevalence in 
the population, a higher positive LR is required to cause a useful increase in the probability 
of disease that may result in a change in management, whereas in a disease of high 
prevalence, a smaller negative LR is required to cause a useful decrease in the probability of 
disease that may result in a change in management. 
For each study we identified in our literature search, we extracted the raw data from 
the paper, rather than summary statistics, in order to obtain true positives, true negatives, 
false positives, and false negatives, into a Microsoft Excel spreadsheet (XP professional 
edition; Microsoft Corp, Redmond, WA, USA), and calculated the sensitivity, specificity, 
positive, and negative predictive values of each of the diagnostic tests for IBS under study. 
The positive and negative LRs, and their 95% confidence intervals (CIs), were also calculated 
within the same spreadsheet, using the aforementioned formulas. Where data were not 
extractable, we attempted to contact the authors of the original paper in order to obtain 
further information.  
Where the accuracy of  identical symptom-based criteria, biomarkers, psychological 
markers, or combinations thereof, were reported by more than one study, we combined the 
LRs from each study using StatsDirect version 2.7.7 (StatsDirect Ltd, Sale, Cheshire, England), 
in order to generate pooled positive and negative LRs with 95% CIs. We also pooled results 
from all studies in order to obtain pooled positive and negative LRs with 95% CIs for each 
approach used to diagnose IBS, including symptom-based criteria alone, biomarkers alone, 
psychological markers alone, and combinations of these.  We used a random effects model 
to provide a more conservative estimate of the accuracy of the various methods, allowing 
for heterogeneity between studies. QUADAS-2, a quality assessment tool for primary 
diagnostic accuracy studies, was used to assess the risk of bias and any applicability 
concerns in the eligible studies.(20) All eligible studies were judged against four key domains 
covering patient selection, the diagnostic test applied, the reference standard, and the flow 
of patients through the study. 
 
 
 
 
RESULTS 
 
 The search strategy identified 3361 citations, of which 33 studies appeared to be 
eligible and were retrieved for evaluation. Twenty-two of these met all eligibility criteria 
(Supplementary Figure 1).(21-42) Agreement between investigators when assessing 
eligibility was excellent (94% agreemenƚ ?ʶA?0.86). The 22 included studies evaluated a total 
of 7106 patients. Eleven of the studies were conducted in Europe, six in North America, four 
in Asia, and one in Australasia. Thirteen of the studies were of cross-sectional design, and 
nine were case-control. As case-control studies are not representative of the true IBS 
prevalence, these were excluded when calculating the pooled prevalence of IBS, which was 
43% (95% CI 37%-50%) in the remaining 13 studies. Twenty-one were conducted in 
secondary care, with one in both primary and secondary care. Individual study 
characteristics are summarised in Supplementary Table 1. The diagnostic tests utilised in the 
eligible studies are shown in Table 2, along with the number of studies assessing the 
accuracy of each test, total number of patients included, and the positive and negative LRs 
with 95% CIs (pooled where appropriate). Study bias and applicability outcomes assessed, 
according to the QUADAS-2 tool, are shown in Supplementary Table 2. Fourteen of the 22 
studies were judged as high risk in one or more of the four key domains. 
 
Symptom-based Diagnostic Criteria 
 Five studies evaluated A?2 of the Manning criteria,(21-24, 27) six studies A?3,(21-24, 
26, 27) and six studies A?4.(21-24, 26, 27) The Rome I criteria were evaluated in three 
studies,(25-27) the Rome II criteria in two studies(26, 27) and the Rome III criteria in only 
one study.(27)  All studies were cross-sectional in design, collected symptom data using a 
questionnaire completed by the patient, and utilised a reference standard of a normal 
colonoscopy or barium enema to confirm the diagnosis of IBS.  
 
The Manning Criteria 
 Pooled positive and negative LRs when using A?2 of the Manning criteria in a total of 
2452 patients were 2.20 (95% CI 1.54-3.14) and 0.18 (95% CI 0.10-0.32) respectively.(21-24, 
27)  In studies assessing A?3 of the Manning criteria,(21-24, 26, 27) accuracy was best in the 
study conducted by Dogan et al.,(24) with a positive LR of 7.15 (95% CI 4.93-10.57) and a 
negative LR of 0.11 (95% CI 0.07-0.17). However, this was not replicated in the five other 
studies, including in the original validation study.(21) The pooled positive and negative LRs, 
in a total of 2966 patients, were 2.85 (95% CI 1.95-4.15) and 0.36 (95% CI 0.24-0.53) 
respectively (Figure 1a and 1b). Finally, when data were pooled from the six studies 
assessing the accuracy of A?4 of the Manning criteria,(21-24, 26, 27) positive and negative 
LRs, in a total of 2986 patients, were 3.43 (95% CI 2.49-4.71) and 0.66 (95% CI 0.60-0.73) 
respectively (Figure 2a and 2b). 
 
The Rome Criteria 
 Pooled positive and negative LRs in the three studies,(25-27) containing 3006 
patients, that reported on the Rome I criteria were 3.20 (95% CI 2.29-4.47) and 0.22 (95% CI 
0.10-0.49) respectively.  Pooled positive and negative LRs of the two studies,(26, 27) 
containing 2402 patients, that evaluated the Rome II criteria were 2.56 (95% CI 1.64-4.00) 
and 0.25 (95% CI 0.08-0.85) respectively. The positive and negative LRs in the one study,(27) 
containing 1848 patients, that reported on the Rome III criteria were 3.35 (95% CI 2.97-3.79) 
and 0.39 (95% CI 0.34-0.46). 
Biomarkers 
 
Visceral Hypersensitivity and Pain Perception as a Biomarker 
 One case control study and one cross-sectional study evaluated the role of visceral 
hypersensitivity using rectal barostat testing(29) and pain perception(30) during 
colonoscopy, in differentiating IBS from healthy controls (HCs) and miscellaneous 
gastrointestinal and medical conditions, in a total of 328 patients. Pooled positive and 
negative LRs in the two studies were 3.71 (95% CI 2.74-5.02) and 0.16 (95% CI 0.10-0.24) 
respectively. One case-control study, containing 138 patients, reported on colonic air 
insufflation to reproduce typical abdominal pain experienced in IBS as a biomarker in 
differentiating the disorder from colonic structural disease.(28) This test performed poorly, 
with positive and negative LRs of 0.98 (95% CI 0.80-1.60) and 1.09 (95% CI 0.40-3.98) 
respectively.  
 
Serum-based Biomarkers 
 The diagnostic accuracy of a serum-based 10 biomarker panel, which were selected 
by examining differences in biomarker expression between IBS patients and HCs (among 
them interleukin-1ß, anti-tissue transglutaminase and anti-neutrophil cytoplasmic 
antibody), was reported in one cross-sectional study(32) and one case-control study(33) 
containing a total of 760 patients, with a pooled positive LR of 3.03 (95% CI 1.49-6.17) and 
pooled negative LR of 0.52 (95% CI 0.43-0.64). In the study conducted by Jones et al.,(33)  an 
additional 24 serum biomarkers, selected through a combination of gene chip human array, 
gene array data analysis and real-time quantitative polymerase chain reaction, were added 
to the original 10 biomarker panel. Positive and negative LRs of the 34 biomarker panel 
were 2.28 (95% CI 1.71-3.17) and 0.30 (95% CI 0.21-0.42) respectively.  
 
Faecal Biomarkers 
 
Volatile Organic Metabolites (VOMs) 
 The diagnostic accuracy of VOMs, chemicals released in faeces and that can undergo 
changes in the presence of organic disease or changes in microbiota, were assessed in one 
case-control study containing 30 IBS patients with diarrhoea, 62 patients with active ƌŽŚŶ ?Ɛ
disease and 48 patients with active ulcerative colitis.(34) Using a receiver operator 
characteristics curve (ROC) to determine optimum performance, the positive and negative 
LRs in differentiating IBS from active inflammatory bowel disease were 4.83 (95% CI 3.36-
7.14) and 0.04 (95% CI 0.01-0.21) respectively.  
 
Chromogranins and Secretogranins 
 Chromogranins (Cg) and secretogranins (Sg) are proteins found in the secretory cells 
of the endocrine, enteric, and immune system. In one case-control study, CgB and SgII and 
SgIII levels were measured in faecal samples from 82 IBS patients and 29 HCs.(35) SgII and 
SGIII levels were higher in the IBS patients, and CgB levels were lower. SgII performed the 
most accurately using a cut-off of >0.16 nmol/g, with a positive LR of 3.89 (95% CI 2.07-8.23) 
and negative LR of 0.25 (95% CI 0.15-0.39).   
 
 
 
Mucosal Intestinal Endocrine Cells as a Biomarker 
 Quantification of CgA cells was performed on biopsy samples taken from the 
duodenum during gastroscopy in one case-control study.(36) Using a cut-off of <200 
cells/mm2, the positive and negative LRs in differentiating 203 IBS patients from 86 HCs, 
were 18.5 (95% CI 7.58-47.3) and 0.14 (95% CI 0.10-0.20). In a similarly designed study,(37) 
rectal biopsies were taken from 50 patients with IBS and 27 HCs. Endocrine cell content was 
quantified and three endocrine cells, (peptide YY, oxyntomodulin and somatostatin) were 
validated as diagnostic tests. Using optimum performance determined on an ROC curve, 
peptide YY performed the best, with a positive LR of 7.56 (95% CI 2.96-21.9) and a negative 
LR of 0.18 (95% CI 0.09-0.33) at a cut-off of <30 cells/mm2. 
 
Sigmoid Muscularis Propria Thickness as a Biomarker 
 In a cross-sectional study of 175 female patients who were undergoing trans-vaginal 
ultrasound for investigation of gynaecological symptoms, sigmoid muscularis propria 
thickness was measured.(31)  A diagnosis of IBS was made using a cut-off for abnormal 
muscularis propria thickness of A?3 mm.  A clinical diagnosis of IBS was confirmed with the 
primary physician and/or Gastroenterologist following ultrasound. Positive and negative LRs 
were 14.9 (95% CI 7.07-31.5) and 0.31 (95% CI 0.17-0.51) respectively. 
 
Combinations of Biomarkers 
 
Faecal Calprotectin (FC) and Intestinal Permeability Ratio as a Biomarker 
In the previously cited study from Tibble et al.,(25) all patients provided a stool 
sample for measurement of FC levels, in addition to undergoing a lactulose/L-rhamnose 
small intestinal permeability test. Using an FC level of <10 mg/L and a permeability ratio of 
<0.05, this biomarker combination was able to identify IBS patients with a positive LR of 
8.64 (95% CI 5.76-13.1) and a negative LR of 0.34 (95% CI 0.28-0.39). 
 
Bile Acid Secretion and Colonic Transit as a Biomarker 
 One case-control study used a 2-item model consisting of total faecal bile acid 
excretion and colonic transit to differentiate between 64 IBS patients with diarrhoea, 30 IBS 
patients with constipation, and 30 HCs.(38) Using the optimum cut-off on an ROC curve, the 
2-item model was able to differentiate IBS from HCs with a positive LR of 2.78 (95% CI 1.55-
5.58) and a negative LR of 0.46 (95% CI 0.33-0.65). 
 
Psychological Markers 
 The use of psychological markers in differentiating IBS from health was evaluated in 
two case-control studies containing 714 patients.(33, 39) In the study conducted by Spiller 
et al. 319 IBS patients and 151 HCs completed the patient health questionnaire 12 (PHQ-12). 
The PHQ-12 differs from the patient health questionnaire-15 (PHQ-15) in that the three 
specific gastrointestinal-related questions are removed. Using a cut-off score of >6, the 
positive LR for the PHQ-12 in differentiating IBS from health was 12.5 (95% CI 6.55-24.6), 
and the negative LR was 0.35 (95% CI 0.30-0.41). Using a cut-off score of >7, the anxiety 
component of the hospital anxiety and depression scale (HADS) was reported to have 
positive and negative LRs of 2.88 (95% CI 2.20-3.86) and 0.37 (95% CI 0.30-0.45) 
respectively. The depression component of the HADS demonstrated positive and negative 
LRs of 5.44 (95% CI 3.01-10.1) and 0.68 (95% CI 0.62-0.75) respectively. 
 In the previously described study conducted by Jones et al.(33), participants were 
asked to complete the HADS, PHQ-15, and the perceived stress scale. Positive and negative 
LRs of these measures of psychological well-being combined in differentiating between IBS 
and HCs were 2.95 (95% CI 2.04-4.48) and 0.35 (95% CI 0.26-0.46) respectively.  
 
Combinations of Symptoms, Biomarkers and Psychological Markers 
 
Kruis Statistical Model 
 The accuracy of the Kruis statistical model, a scoring system that incorporates the 
clinical history, physical examination, and blood tests (erythrocyte sedimentation rate (ESR), 
leucocyte count, and haemoglobin level), was assessed in four cross-sectional studies, 
including a total of 1171 patients.(24, 40-42) A score of A?44 was used as the cut-off to 
diagnose IBS. The pooled positive LR of these studies as assessed in a previous meta-
analysis,(16) as there have been no studies published in the interim, was 8.63 (95% CI 2.89-
25.8) and the pooled negative LR was 0.26 (95% CI 0.17-0.41).  
 
Other Statistical Models 
 Frigerio et al.,(42) in a cross-sectional study, lowered the predetermined cut-off 
point of haemoglobin level in the Kruis statistical model from 14g/100ml to 13g/100ml in 
males and from 12g/100ml to 11g/100ml in females. Positive and negative LRs for this 
modified model, containing 253 patients, were 7.73 (95% CI 4.83-12.4) and 0.34 (95% CI 
0.22-0.49) respectively.  
 Although differing from the Kruis model in the items included, the model validated in 
the cross-sectional study by Bellentani et al.,(41) also incorporated the clinical history, 
physical examination, and an ESR and leucocyte count. Positive and negative LRs for this 
statistical model, containing 254 patients, were 4.29 (95% CI 2.86-6.66) and 0.30 (95% CI 
0.22-0.39) respectively. 
 
A Combination of FC, Intestinal Permeability Ratio, and the Rome I Criteria   
In the previously described study by Tibble et al.(25), if a positive result for the Rome 
I criteria was incorporated with FC levels of <10mg/L and permeability ratio of <0.05, the 
positive and negative LRs were 26.4 (95% CI 11.4-61.9) and 0.51 (95% CI 0.45-0.56) 
respectively. 
 
A Combination of Serum-based Biomarkers and Psychological Markers 
 Finally, in the study conducted by Jones et al.(33), the serum-based 34 biomarker 
panel and psychological measures were combined to ascertain if this improved accuracy in 
diagnosing IBS. Positive and negative LRs for this combined approach in differentiating IBS 
from health were 7.14 (95% CI 4.01-13.3) and 0.18 (95% CI 0.12-0.25) respectively.  
 
Pooled Positive and Negative LRs for Each Approach Used to Diagnose IBS 
When individual study results were combined to obtain pooled positive and negative 
LRs for each of the approaches to diagnose IBS, using all available studies for each of the 
approaches they assessed, there were significant differences in the pooled positive LR 
between studies using symptom-based criteria alone (positive LR 2.85; 95% CI 2.53-3.20), 
and studies that used a combination of symptoms, biomarkers, and psychological markers 
(positive LR = 8.48; 95% CI 4.64-15.5), but not between any of the other methods (Figure 
3a). Negative LRs were not significantly different for any of the four approaches (Figure 3b).   
DISCUSSION 
 
 This study has examined the accuracy of symptom-based diagnostic criteria, 
biomarkers, psychological markers or combinations thereof, in making a diagnosis of IBS. 
The Rome III criteria, the current gold standard for the diagnosis of IBS, have only been 
validated in one study to date, and performed modestly and similarly to the other symptom-
based diagnostic criteria that have been described previously, with a positive LR >3 and a 
negative LR of approximately 0.4. Proposed biomarkers, with the exception of abnormal 
sigmoid muscularis propria thickness in female patients, intestinal mucosal endocrine cells, 
and faecal VOMs, and a combination of FC and intestinal permeability, all examined in single 
studies, appeared to perform no better than available symptom-based diagnostic criteria. 
The accuracy of psychological markers was also similar. Combining symptoms, biomarkers, 
and/or psychological markers in various permutations seemed to perform better generally 
in diagnosing IBS, and with a significantly greater pooled positive LR compared with 
symptom-based criteria. 
 Strengths of this study include a comprehensive search strategy, including a 
recursive search of the bibliographies of all eligible studies, and searching of conference 
proceedings to identify any potential studies published that may not have been included in 
the original search of the medical literature. This resulted in the identification of a wide 
range of potential methods for diagnosing IBS; specifically four different symptom-based 
diagnostic criteria evaluated in seven studies, eleven biomarkers evaluated in twelve 
studies, four psychological markers evaluated in two studies, and five different 
combinations of symptoms, biomarkers, and/or psychological markers evaluated in six 
studies. Pooling the data in some of our analyses resulted in a study population of 1800 
patients or more for each of the symptom-based diagnostic criteria, and >1000 patients for 
the Kruis statistical model. Furthermore, this is the first study that has attempted to 
summarise data from all available methods, including novel approaches, to diagnose IBS.  
 There are some limitations to this study. When data were pooled, results varied 
between individual studies that evaluated the same diagnostic method in some analyses, 
which may be partly explained by differences in study design, recruitment, setting, and 
country, and differences in the reference standard used for diagnosing IBS. However, we 
used a random effects model when pooling study data in all these analyses, in order to 
provide a more conservative estimate of diagnostic accuracy. The cut offs we used to define 
presence of IBS for each of the diagnostic tests assessed in this meta-analysis was imposed 
by the reporting of the authors of the original studies. This is less relevant for studies 
employing diagnostic criteria, such as the Manning criteria, because we were able to obtain 
data for several thresholds, but is an issue for studies using laboratory tests, such as faecal 
chromogranins or VOMs, or the measures of psychological affect, which were not always 
used at the threshold recommended by the original authors. Additionally, the pooled IBS 
prevalence of all studies was high at >40%, as the majority of studies were conducted in 
referral populations in secondary care, meaning that some of the findings may not be 
applicable to a primary care setting, where the majority of patients are diagnosed and 
managed, as the prevalence of IBS may well be lower. The inclusion of case-control studies 
may lead to an overestimation of the diagnostic performance of the test being examined, 
compared to studies using a clinical cohort, because these are subject to spectrum bias as 
the study design often omits mild cases that are difficult to diagnose.(43) Finally, 14 of the 
22 eligible studies were judged as high risk of bias, or had other applicability concerns, when 
assessing quality using the QUADAS-2 tool, highlighting the limitations of some of the 
studies. 
In terms of our use of LRs, the advantage of these is that they provide the clinician 
with an intuitive feeling on ruling in or ruling out a given disease based on the magnitude of 
the positive and negative LRs respectively, and are less likely to be influenced by prevalence 
of the disease of interest than predictive values. However, there are some disadvantages to 
using LRs. In particular, LRs are not often quoted in the medical literature, the main reason 
being that clinicians are more used to dealing with probabilities as in the case of predictive 
values, whereas LRs express their results in terms of odds.(19)  Another disadvantage is that 
LRs can have wide confidence intervals, particularly in rare diseases with a low prevalence. 
However, this is of less relevance to IBS, which has a prevalence of 10% to 20% in the 
general population.(2) We have provided sensitivities, specificities, and positive and 
negative predictive values for each of the diagnostic tests applied in Supplementary Table 3.  
 Guidelines for the management of IBS recommend making a positive diagnosis of IBS 
based on symptoms, and discouraging a  “diagnosis of exclusion ?ĂƉƉƌŽĂĐŚ.(44, 45) 
Symptom-based diagnostic criteria were developed to aid in this, and therefore avoid 
unnecessary and potentially invasive investigations. However, one of the most consistent 
findings of this study is the modest performance of all the available symptom-based criteria 
in identifying IBS. This comparable performance between the symptom-based criteria is 
perhaps not surprising, considering they are derivatives of each other, and therefore share 
the same strengths and weaknesses.  
 In general, the performance of biomarkers in the studies we identified was similar to 
symptom based criteria, which is disappointing considering their potentially expensive 
nature. In some cases, the biomarkers would not be considered useful as a test outside of a 
tertiary referral centre, due to the invasive nature or complexity of the test applied. 
Furthermore, a number of the studies that assessed the accuracy of biomarkers used 
healthy volunteers as controls, whereas a biomarker that differentiated IBS from other 
organic disorders, in which the symptoms are likely to overlap with those of IBS, would be 
more clinically useful. Sigmoid muscularis propria measurement using trans-vaginal 
ultrasound, appeared to perform well with a positive LR of 15. However, this study had a 
number of limitations, including the failure to exclude other causes of abnormal muscularis 
propria thickness, such as colorectal cancer, inflammatory bowel disease, or diverticular 
disease, only 27 patients in the study population having a confirmed diagnosis of IBS, and 
the generalisability of the results, given that the test was applied in female patients only. 
Additionally, the results have yet to be validated by other investigators, despite the study 
being published 8 years ago. Duodenal mucosal CgA cell quantification also performed well 
in differentiating IBS from health, but only in a single study, and the test is invasive.  In 
addition, the effect of coeliac disease, duodenitis, duodenal ulcers or inflammatory bowel 
disease on numbers of CgA cells in the duodenum has not been studied, and therefore 
further work in this area is required before any definitive conclusion can be made from this 
study.  Faecal VOMs showed some promise in differentiating IBS from active inflammatory 
bowel disease in one small study, but again results of this study will require validating by 
others. 
 Given the known association of IBS with somatic symptoms and mood disorders 
demonstrated by others,(46) it is perhaps surprising that the performance of psychological 
markers were, in general, no better than that of symptom-based criteria. One possible 
reason that studies evaluating psychological markers performed poorly, was that these 
predominantly used markers of anxiety and depression to predict presence of IBS. In a 
recently conducted study, where somatisation data were collected from more than 4000 
patients referred to secondary care for investigation of their symptoms,(47) mean 
somatisation scores and mean number of somatic symptoms reported were significantly 
higher in 840 patients with IBS compared with 2137 patients without IBS, but who still 
reported GI symptoms. These findings support those of Spiller et al.,(39) where somatisation 
was found to be superior to either anxiety or depression.  Somatisation as a marker may 
therefore be more accurate in predicting the presence of IBS than other measures of 
psychological well-being. More focused measures of psychological affect such as worry or 
rumination, which may also be associated with IBS,(48) could provide fruitful avenues for 
future research. An additional issue is the fact that the two studies reporting on the 
accuracy of psychological markers differentiated IBS from health, and therefore whether 
psychological markers can accurately discriminate between IBS and organic gastrointestinal 
disorders is unclear. This would seem less likely, as there is evidence to suggest that many 
organic GI disorders are also associated with psychological impairment.(49-51)  
 Combinations of symptoms, biomarkers, and/or psychological markers seemed to 
perform better, generally, in the six studies that assessed the accuracy of these approaches, 
and were superior to symptom-based criteria in terms of the pooled positive LR. This may 
be because IBS is a complex, heterogeneous disorder, for which there is no single unifying 
explanation, and for which numerous mechanisms have been proposed.(52-56) Combining 
symptoms or examination findings, biomarkers and/or psychological markers may therefore 
be a more useful approach to diagnosing IBS, and perhaps points the way forward for future 
iterations of the Rome process. However, this approach will likely result in increasing 
complexity of the diagnostic test, and may reduce its practicality in a clinical setting. This is 
probably the main reason that the Kruis statistical model was never adopted widely, despite 
its apparently superior performance in predicting IBS accurately. Any future set of diagnostic 
criteria would also need to be easily administrable and interpretable in a primary care 
setting, and this again probably explains why the combination of FC, intestinal permeability 
ratio, and Rome I criteria did not progress beyond a research setting, despite its accuracy.  
Our findings highlight that existing diagnostic approaches are unable to define IBS 
with any great accuracy. An alternative strategy may be to use latent class analysis methods. 
These are designed to use available information to create an appropriate pattern of 
measurements that most closely represents the latent construct IBS, and define groups, or 
classes, which could serve as a way of improving the accuracy of methods used to diagnose 
IBS, and therefore help to discriminate between IBS and non-IBS symptom profiles. 
However, at the time of writing, there are only a few instances of this type of modelling 
being used in functional GI disorders.(57) These complex statistical methods have the 
potential to explore a combination of patient-reported, endoscopic, and biochemical 
variables, in order to develop a stronger predictor of IBS, which could then be employed in 
everyday practice in the clinic by exploiting technological advancements, such as 
smartphone applications. These novel methods to aid the diagnosis of IBS could also be 
used to assess clinically meaningful dependent variables, such as response to therapy, 
health care consumption, and quality of life.  
 In conclusion, this meta-analysis has shown that symptom-based diagnostic criteria, 
biomarkers, and psychological markers perform only moderately well in diagnosing IBS, and 
in the case of biomarkers many of these are potentially expensive or invasive, and are not 
yet practical for clinical application. Combining symptoms with markers of organic disease 
or psychological affect, for instance using latent variable models, may represent the best 
way forward in improving the accuracy of diagnosing IBS.  
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Table 1: Eligibility criteria for studies to be included in the systematic review. 
Eligibility criteria 
Adult patients (aged > 16 years) with lower GI symptoms 
Cross-sectional design or case-control 
Applied a diagnostic test for IBS to all patients, including one or more of: symptom-
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Table 2: Pooled Positive and Negative Likelihood Ratios (LRs) of Diagnostic Tests for 
Irritable Bowel Syndrome. 
 
 Diagnostic test 
applied 
No. of 
studies 
No. of 
patients 
Positive LR  
(95% CI) 
Negative LR  
(95% CI) 
Symptom-based 
diagnostic 
criteria 
DĂŶŶŝŶŐA䠃?criteria 5 2452 2.20 (1.54-3.14) 0.18 (0.10-0.32) 
DĂŶŶŝŶŐA䠃?ĐƌŝƚĞƌŝĂ 6 2966 2.85 (1.95-4.15) 0.36 (0.24-0.53) 
DĂŶŶŝŶŐA䠃?ĐƌŝƚĞƌŝĂ 6 2986 3.43 (2.49-4.71) 0.66 (0.60-0.73) 
Rome I 3 3006 3.20 (2.29-4.47) 0.22 (0.10-0.49) 
Rome II 2 2402 2.56 (1.64-4.00) 0.25 (0.08-0.85) 
Rome III 1 1848 3.35 (2.97-3.79) 0.39 (0.34-0.46) 
Biomarkers Visceral 
hypersensitivity 
2 328 3.71 (2.74-5.02) 0.16 (0.10-0.24) 
Pain perception 1 138 0.98 (0.80-1.60) 1.09 (0.40-3.98) 
Serum-based 10 
biomarker panel 
2 760 3.03 (1.49-6.17) 0.52 (0.43-0.64) 
Serum-based 34 
biomarker panel 
1 244 2.28 (1.71-3.17) 0.30 (0.21-0.42) 
Volatile organic 
metabolites in faeces 
1 140 4.83 (3.36-7.14) 0.04 (0.01-0.21) 
Chromogranins and 
secretogranins in 
faeces: 
Secretogranin II 
Secretogranin III 
Chromogranin B 
 
 
 
1 
1 
1 
 
 
 
111 
111 
111 
 
 
 
3.89 (2.07-8.23) 
2.59 (1.61-4.70) 
2.51 (1.56-4.56) 
 
 
 
0.25 (0.15-0.39) 
0.28 (0.17-0.47) 
0.32 (0.20-0.51) 
Duodenal 
chromogranin A 
1 289 18.5 (7.58-47.3) 0.14 (0.10-0.20) 
Rectal endocrine cells: 
Peptide YY 
Oxyntomodulin 
Somatostatin 
 
1 
1 
1 
 
77 
77 
77 
 
7.56 (2.96-21.9) 
4.32 (2.14-9.87) 
7.20 (2.81-20.9) 
 
0.18 0.09-0.33) 
0.25 (0.14-0.43) 
0.23 (0.12-0.38) 
Sigmoid muscularis 
propria thickness 
1 175 14.9 (7.07-31.5) 0.31 (0.17-0.51) 
FC and small intestinal 
permeability ratio 
1 602 8.64 (5.76-13.1) 0.34 (0.28-0.39) 
Bile acid secretion and 
colonic transit 
1 124 2.78 (1.55-5.58) 0.46 (0.33-0.65) 
Psychological 
markers 
PHQ-12 score 1 470 12.5 (6.55-24.6) 0.35 (0.30-0.41) 
Anxiety component of 
the HADS 
1 470 2.88 (2.20-3.86) 0.37 (0.30-0.45) 
Depression 
component of the 
HADS 
1 470 5.44 (3.01-10.1) 0.68 (0.62-0.75) 
Combination of HADS, 
PHQ-15, and the 
perceived stress scale 
1 244 2.95 (2.04-4.48) 0.35 (0.26-0.46) 
Combinations of 
symptoms, 
biomarkers, 
and/or  
psychological 
markers 
Kruis et al. statistical 
model 
4 1171 8.63 (2.89-25.8) 0.26 (0.17-0.41) 
Modified Kruis 
statistical model 
1 253 7.73 (4.83-12.4) 0.34 (0.22-0.49) 
Bellentani et al. 
statistical  model 
1 254 4.29 (2.86-6.66) 0.30 (0.22-0.39) 
FC, small intestinal 
permeability ratio, and 
Rome criteria 
1 602 26.4 (11.4-61.9) 0.51 (0.45-0.56) 
Serum-based 34 
biomarker panel and 
psychological markers 
1 244 7.14 (4.01-13.3) 0.18 (0.12-0.25) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1a: Pooled Positive Likelihood Ratio of ш3 Manning Criteria. 
Figure 1b: Pooled Negative Likelihood Ratio of ш3 Manning Criteria. 
Figure 2a: Pooled Positive Likelihood Ratio of ш4 Manning Criteria. 
Figure 2b: Pooled Negative Likelihood Ratio of ш4 Manning Criteria. 
Figure 3a. Pooled Positive Likelihood Ratios for All Approaches to the Diagnosis of IBS. 
Figure 3b. Pooled Negative Likelihood Ratios for All Approaches to the Diagnosis of IBS. 
